Age spots, also called Lentigo senilis, are small, localised, sharply circumscribed sites of hyperpigmentation of the skin. Contrary to freckles, which are due to an UV-induced increased, but reversible production of melanin, lentigines are caused by local hyperplasia (cell proliferation) at the basal layer of the epidermis.
Melasma, another symptom of hyperpigmentation and of aesthetic concern to Asian population, is characterised by diffuse patches of brownish colour, often induced by hormonal imbalance (‘pregnancy masks’) and sometimes reversible.
Physiology of pigmentation
In order to understand the causes of age spots, it is worth first looking at the physiology of skin pigmentation (Fig. 1). Melanocytes are embedded at the base of the epidermis, close to the epidermal/ dermal junction. From a single melanocyte, dendrites (finger like extensions) reach out to the surrounding keratinocytes (about 35-40 of those are in contact with one melanocyte, this entity being called the melanin unit). In the melanocyte, small organelles, called melanosomes, are formed continuously and migrate to the extremities of the dendrites. These melanosomes are the true ‘factories’ of melanin production: they contain a large number of copies of the enzyme tyrosinase, which is a key molecule in the synthetic pathway of melanin. Tyrosinase needs the amino acid tyrosine as the initial substrate for melanin synthesis, which proceeds from tyrosine to dopa, to dopaquinone, to leucodopachrome, to 5,6 indolequinone and via polymerisation steps to melanin. The melanosomes are then transferred to the surrounding keratinocytes in a process that resembles phagocytosis.
Tyrosinase and UV irradiation
Several of these transformative steps are catalysed by tyrosinase, and are based on the oxidising power of this enzyme. The process is however more complex than can be described here, a number of side-tracks and alternative paths can be activated, such that tyrosinase inhibition alone is rarely successful in treating hyperpigmentation. Tyrosinase is not the only story; we need to look at upstream events, linked to UV irradiation: solar rays (UVB) stimulate keratinocytes to produce POMC (proopiomelanocortine) which is then metabolised to MSH, the melanin stimulating hormone. It attaches to the MC1R receptor of melanocytes, activates adenylcyclase, leading to an increased amount of cAMP. Via PKA, CREB and MITF transcription factors, increased production of tyrosinase is initiated, in the end leading to more melanin. However, it is not only UV radiation that can cause hyperpigmentation; inflammatory processes (caused by medication, injections and other stresses) as well as hormonal imbalance (estrogens) are well known to induce free radical production, increase in pigmented macrophages and increased melanin production. The appearance of age spots requires one more explanation: why is the hyperpigmentation symptom not homogenous, but localised? Recent studies by the LVMH company have begun to elucidate the reasons. The epidermal/ dermal junction (EDJ) is not a flat sheet but a very convoluted curvy structure, where so-called rete ridges extend more or less deeply into the dermal tissue. It is in these rete ridges that pigmentation accumulates, especially when the EDJ is disrupted and disorganised, e.g. as a consequence of inflammation, traumatic stress, metabolic perturbations. Consequently, increased amounts of interleukin 1, GM-CSF and endothelin-1 are released by keratinocytes, which are all signals for increased melanin production. Investigations by Shiseido have revealed another culprit: heparanase, an enzyme that degrades heparin sulfate at the epidermal basement membrane causes epidermal hyperplasia, increase in blood vessel generation and increased melanin synthesis. This is further confirmation for the observation that disruptive processes at the basal membrane are – at least partially – responsible for excessive pigmentation at the local level. The researchers also saw that inhibiting the heparanase enzyme decreased melanogenesis.
This brings us to the question of possible cosmetic treatments and counteractions. From the preceding paragraphs it becomes evident that a number of attack points exist:
• Inhibition of the tyrosinase enzyme and/or of its activation within the melanocyte. • Enhancement of the enzyme’s degradation and disappearance. • Downregulation of MC1R activity and inhibition of MITF transcription.• Interference with melanosome maturation and transfer.• Inhibition of heparanase. • Increase in desquamation and chemical peeling to remove older pigmented cells.
Classical melanogenesis inhibitors have been described over many years: hydroquinone (HQ) was used for a long time for ‘skin whitening’, until its risks to human health became too obvious to overlook, and it is now banned in most countries. Arbutin, the glycosylated form of HQ is reputed to be less toxic; it binds to tyrosinase and inhibits its activity. Kojic acid acts mostly by specific sequestering of the copper ions needed for tyrosinase activity; this substance also raised toxicological concerns. Widely used are ascorbic acid (vitamin C) and its derivatives for their considerable anti-oxidant activity (we have seen that melanin synthesis requires several oxidation steps with which any anti-oxidant might interfere). The mechanisms by which retinoids act on melanin synthesis appear to be many, but at the same time confusingly so. As lentigo – although localised – is still caused by excessive melanogenesis based on the same mechanisms as elsewhere in the skin, there is little chance of finding specific products to treat these age spots. What works on melanin synthesis in general will work on age spots, maybe even more. This is also claimed for a novel analogue of arbutin, called Deoxyarbutin, recently patented and licensed to an American company. A literature survey of recent attempts to find new melanogenesis inhibitors turns up various exotic substances, such as platycodin D, acting on the cAMP/ MITF pathway and reducing inflammation; DMHF, a natural furanone that acts on CREB, MITF and tyrosinase transcripton; diosgenin (yam extract) interfering with the PI3K pathway and MITF; quercetin (from oak bark) that reduces TRP1 and TRP2 expression, and diminishes cAMP production; and zeolite A4, an aluminum silicate which appears to have multiple activities including copper chelation, calcium transport inhibition and MITF reduction. Better documented and studied approaches involve a derivative of the natural boldine substance (diacetylboldine) which inhibits ,adrenergic receptors, calcium transport and PKC activation of tyrosinase, leading to measurable skin lightening, including phototype V and VI skins and age spots on Caucasian skin. A specific hop extract rich in xantohumol was shown to interfere with the all important keratinocytemelanocyte communication (via GM-CSF) and the -catenin pathway in melanocytes. Genomic analysis allowed the mechanisms to be well understood, while clinical data showed the pertinence of the concept. Niacinamide and oridonine (a Rabdosia rubescens extract) are active by inhibiting melanosome transfer and melanin uptake by keratinocytes; some anti-inflammatory plant extracts of recent development (tomato extracted phytoenes, Narzissus tazetta bulb extract, sea lily extract, Rheum rhaponticum extract) might also be mentioned.
In conclusion it is important to understand that melanin synthesis is a highly complex process that is still only partly understood and which involves too many parallel pathways for a single active ingredient to be significantly effective. A multi-pronged approach to skin lightening is therefore recommended. Care must be taken to evaluate ideas and substances not only on mouse melanoma B16 cells, but also on normal human melanocytes, on 3D skin models of various provenance and skin types, and finally in well conducted clinical trials.
Karl Lintner has 20 years of wide ranging experience in personal care, allowing him to assist companies by bringing ‘Beauty Ideas to the Beauty Counter’, from mass market to luxury brands, from anti-ageing to whitening, from me-too to exclusive high-tech. Karl is also an Associate Professor at Versailles St. Quentin University in France and has kindly given his time to give free training to the formulators in Asia via FormulaCare webinars. His presentation, ‘Age spots: causes and cosmetic treatments’, formed the basis of this article. For more information on FormulaCare visit www.formulacare.com
Picture courtesy of Sederma
Founded in 1959, Ichimaru Pharcos is a global leader in Research and Development of natural active ingredients for the cosmetic industry. Located in Gifu prefecture, Japan, Ichimaru Pharcos gained reputation and trust from world leading cosmetic brands to small scale cosmetic manufactures with its efficient support and service. We...
Learn more »
Pier 36, New York City, USA
7 - 8 September 2016
Palau de Congressos de Barcelona. Fira 1, Spain
28 - 29 September 2016
Expo Center Norte, São Paulo, Brasil
5 - 6 October 2016
Esperanto Hotel, Fulda, Germany
12 - 14 October 2016
19 - 20 October 2016
Sederma unveils a new approach to pollution defence
Register now to apply for regular copies of Personal Care Magazine and free access to premium content, as well as our regular newsletters.
SERENE BEAUTY: Lubrizol Skin Care’s new approach to beauty
Register now to apply for regular copies of Personal Care Europe and free access to premium content, as well as our regular newsletters.
그린테크: 변화하는 세계의 길목에서
Register now to apply for regular copies of Personal Care Language and free access to premium content, as well as our regular newsletters.
Don't miss out on the latest news and technology affecting professionals involved in personal care product design, development and manufacture. Register FREE for our regular newsletters now, and enjoy FREE access to feature article content and to the digital versions of Personal Care Magazine.